RO7771950

RO7771950 (A-1041, RG6596) is a small-molecule drug developed by Hoffmann-La Roche. Its target is HER2 (the sponsor names HER2). The sponsor states: A blood-brain-barrier-penetrant HER2-targeted inhibitor, studied orally in combination with trastuzumab and capecitabine in HER2-positive breast cancer, including patients with CNS metastases. ClinicalTrials.gov describes the intervention as: Participants will receive one of two doses of RO7771950 orally (PO) twice a day (BID). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07413939 (RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive), in HER2-positive breast cancer and HR-positive / HER2-negative breast cancer. The largest, NCT07413939, plans to enrol 650 participants with primary completion expected 2029-05-01. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.